CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Melphalan HCl for injection (propylene glycol free)drug
Likely dose
Melphalan HCl for injection (propylene glycol free) 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02669615
NCT02669615Phase 2Completed
CompareCT.gov

A Phase II, Open-Label, Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

Medical College of Wisconsin·interventional·Posted Feb 1, 2016·Updated Oct 10, 2018

In Brief

A Phase 2 clinical trial evaluating Melphalan HCl for injection (propylene glycol free) for Multiple Myeloma. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This study is a single-center, open-label study of high-dose Melphalan HCl (hydrochloric acid) for injection (propylene glycol-free Melphalan) conducted in 24 patients, who have symptomatic multiple myeloma and qualify for autologous stem-cell transplantation (ASCT). There will be three distinct evaluation periods in this trial: a pretreatment period, a study period and a follow-up period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 1, 2016
Enrollment StartNov 1, 2016
Primary CompletionJun 9, 2017
Study CompletionJul 19, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.4 years ago

Interventions

Melphalan HCl for injection (propylene glycol free)drug

During the study period, patients will receive 200 mg/m\^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.